The inhibition of ACSL4 by rosiglitazone could significantly attenuate impulsive and depression-like behaviors in MRL/lpr mice, with increased expression of GPX4 and decreased lipid peroxidation indicators in the brain parenchyma. Here, GPX4 is linked to major depressive disorder.